BioArctic AB (publ) (BIOA-B.ST) Stock Analysis & Winston Score

BioArctic is a Swedish biotechnology company that focuses on developing treatments for brain diseases, especially Alzheimer's disease. Its most important product is lecanemab, a drug that targets and removes harmful protein clumps in the brain that are linked to Alzheimer's. The drug is sold under the brand name Leqembi and was developed together with the Japanese pharmaceutical company Eisai. BioArctic earns money mainly through royalties and milestone payments from its partnership with Eisai, which handles most of the global sales and commercialization of Leqembi. The company is based in Stockholm, Sweden, and while it is relatively small in terms of staff, its market value has grown significantly since Leqembi received approval in the United States in 2023. The key growth driver is the continued rollout of Leqembi across major markets, including the US, Japan, and potentially Europe, though the main risk is that reimbursement approvals and slow patient uptake could limit how quickly revenue grows.